Therapeutic application of histone deacetylase inhibitors for central nervous system disorders.
about
Proteome-wide lysine acetylation in cortical astrocytes and alterations that occur during infection with brain parasite Toxoplasma gondiiA novel small molecule hydroxamate preferentially inhibits HDAC6 activity and tumour growthAn epigenetic blockade of cognitive functions in the neurodegenerating brainClinical and experimental applications of sodium phenylbutyrateEpigenetics of nicotine: another nail in the coughingCurrent and future pharmacological treatment strategies in X-linked adrenoleukodystrophyMacrocyclic histone deacetylase inhibitorsEvaluating genetic markers and neurobiochemical analytes for fluoxetine response using a panel of mouse inbred strainsThe chemical complexity of cellular microtubules: tubulin post-translational modification enzymes and their roles in tuning microtubule functionsEpigenetic Regulation of Oxidative Stress in Ischemic StrokeDiagnostic workup and management of patients with suspected Niemann-Pick type C diseaseAge-associated Cognitive Decline: Insights into Molecular Switches and Recovery AvenuesTargeting New Candidate Genes by Small Molecules Approaching Neurodegenerative Diseases5p deletions: Current knowledge and future directions.HDAC8 substrates: Histones and beyondSmall molecule inhibitors of zinc-dependent histone deacetylasesGrowing the growth cone: remodeling the cytoskeleton to promote axon regenerationTargeting histone deacetylases for cancer therapy: from molecular mechanisms to clinical implicationsNuclear receptor coregulators: modulators of pathology and therapeutic targetsGenetic, transcriptomic, and epigenetic studies of HIV-associated neurocognitive disorderProtein homeostasis as a therapeutic target for diseases of protein conformationEpigenetic control of gene expression in the alcoholic brainHistone deacetylases and their role in motor neuron degenerationExpression of ethanol-induced behavioral sensitization is associated with alteration of chromatin remodeling in miceHDAC4 reduction: a novel therapeutic strategy to target cytoplasmic huntingtin and ameliorate neurodegenerationAtomic resolution structure of human -tubulin acetyltransferase bound to acetyl-CoADynamic self-guiding analysis of Alzheimer's disease.Targeting histone deacetylases: perspectives for epigenetic-based therapy in cardio-cerebrovascular diseaseThe promise and perils of HDAC inhibitors in neurodegenerationDrosophila as an In Vivo Model for Human Neurodegenerative DiseaseGenome-wide mapping of HATs and HDACs reveals distinct functions in active and inactive genesDietary phytochemicals, HDAC inhibition, and DNA damage/repair defects in cancer cellsIdentifying unexpected therapeutic targets via chemical-protein interactomeEvaluation of histone deacetylases as drug targets in Huntington's disease models. Study of HDACs in brain tissues from R6/2 and CAG140 knock-in HD mouse models and human patients and in a neuronal HD cell modelHuman disease-drug network based on genomic expression profilesArabidopsis HDA6 regulates locus-directed heterochromatin silencing in cooperation with MET1Oral administration of the pimelic diphenylamide HDAC inhibitor HDACi 4b is unsuitable for chronic inhibition of HDAC activity in the CNS in vivoGreen tea extract increases mRNA expression of enzymes which influence epigenetic marks in newborn female offspring from undernourished pregnant motherLimited Effect of Chronic Valproic Acid Treatment in a Mouse Model of Machado-Joseph DiseaseSelective toxicity by HDAC3 in neurons: regulation by Akt and GSK3beta
P2860
Q22255525-69350763-26D2-4362-9FDC-B65D93F4B787Q24309277-201A93C8-F3A2-469B-9CDA-9C3CCB9DD4A4Q24611928-9E6759C7-BE3D-419F-B9FA-456995840884Q24613511-490B021D-41DF-44C9-874F-CAB7B8DC4779Q24616185-3522678A-0103-493D-970B-4842A5727A21Q24618949-6BD98A8A-D1E0-4985-9830-86D4379670C2Q24629065-BBCC63C8-1F66-4281-9E11-67A2523F85ACQ24632901-80289664-4B41-4E53-8972-751DEC6E39F2Q24633494-E86B79ED-11DE-45F6-89C0-83A14534D8D5Q26743597-0001CFE1-343A-4B9D-833F-9040309DF690Q26748586-28D87A58-3FF1-4AD1-B32E-B8C9F998437DQ26750184-DB5D17D6-A011-4656-9019-1F5D325F8FFFQ26771812-B28C93EA-4D1B-4CD9-9F61-2B4614F435DEQ26800129-A6C8FF7F-673A-4997-905F-FAF39BE548CEQ26824122-1DD1FEDC-0313-4C38-BF9F-34CD1484459AQ26824515-BFE139D8-212F-4971-AE6F-FBD6D613BC14Q26829489-B843A4DE-CC01-4CD2-99E1-C88ABD9567B8Q26853394-9F3C3204-D279-4380-A480-2844BC7DFA36Q26859163-B487E3B5-34CB-4045-A255-E8B3BA008C98Q26865707-78E27E1C-7F9B-41D7-BE28-BCDB2230B067Q27003283-4CAD03F5-5B80-4E7C-9FFE-AD51AE6A703BQ27014929-7AA22889-0F60-4BD1-A955-F33D3756121FQ27021381-415B4FEB-0FCC-44C7-904F-A2C4A620C578Q27313868-487F72AB-E5F6-4E48-BD3E-A0B65876C155Q27316520-FB487B74-8DE8-4AF2-AA85-C54E71752778Q27674573-77D2DF76-4D81-425E-9831-46EED335D111Q28080897-F231EACD-E265-4412-B43C-00EBB8BC807DQ28085588-A8FB853B-707B-4408-ACB5-E6CAE4965427Q28087539-7827A521-0E53-4883-A8FA-973FF91833CBQ28088777-43355631-3B53-419D-8D02-9C1E40B5C062Q28255974-B5641A0D-3C7A-48F7-85A2-EB8C31A57D88Q28257534-119494EC-B793-4A0C-9722-1EEC6ACC5EBBQ28473107-E5ADBB87-6B6B-443E-9E52-445BEE5FC190Q28475537-D62F7875-3FF8-4AD0-A968-44293CFA7B67Q28475892-8BD92FBA-8E1B-4E6A-B4C4-B0678B3466BFQ28477923-1DAF694A-7CD4-4DBF-B3E4-5194949FCDDBQ28483335-E90CC068-FA37-4998-BE58-F03E48F21959Q28536018-289321A4-FB97-4CCB-A37F-96999DC2D034Q28550502-EE5178A1-6056-4BA6-97F5-E27B403D4205Q28565080-AD3AA8E4-9C19-43BA-9AD5-64DC9F0AF936
P2860
Therapeutic application of histone deacetylase inhibitors for central nervous system disorders.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on October 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Therapeutic application of his ...... tral nervous system disorders.
@en
Therapeutic application of his ...... tral nervous system disorders.
@nl
type
label
Therapeutic application of his ...... tral nervous system disorders.
@en
Therapeutic application of his ...... tral nervous system disorders.
@nl
prefLabel
Therapeutic application of his ...... tral nervous system disorders.
@en
Therapeutic application of his ...... tral nervous system disorders.
@nl
P356
P1476
Therapeutic application of his ...... tral nervous system disorders.
@en
P2093
Aleksey G Kazantsev
Leslie M Thompson
P2888
P304
P356
10.1038/NRD2681
P577
2008-10-01T00:00:00Z